<DOC>
	<DOCNO>NCT00193557</DOCNO>
	<brief_summary>This phase I study evaluate feasibility toxicity weekly bortezomib treatment relapse refractory multiple Myeloma determine whether twice-weekly schedule bortezomib effective produce response patient stable disease progression weekly bortezomib</brief_summary>
	<brief_title>Weekly Bortezomib ( Velcade ) Treatment Patients With Refractory Multiple Myeloma</brief_title>
	<detailed_description>Upon determination eligibility , patient receive : - Bortezomib</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<criteria>To include study , must meet following criterion : Multiple Myeloma Received 2 previous treatment regimens multiple Myeloma ECOG performance status 0 , 1 , 2 Serum creatinine &lt; 2.0mg/dL calculate measure creatinine clearance &gt; 30ml/minute Measurable evaluable disease Provide write informed consent prior receive protocol therapy . You participate study follow apply : Moderate severe peripheral neuropathy Other serious medical condition Other active malignancy history treatment invasive cancer Women pregnant lactate Please note : There additional inclusion/exclusion criterion . The study center determine meet criterion . If qualify trial , study personnel explain reason . If qualify , study personnel explain trial detail answer question may .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2009</verification_date>
</DOC>